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Time	(min)	 Flow	rate		(ml/min)	 %A	 %B	 Curve	
0	 0.4	 30 70 	
18.99	 0.4	 30	 70	 6	
19.00	 0.4	 20	 80	 1	
22.00	 0.4	 20 80 6	
24.00	 0.4	 0	 100	 6	
29.00	 0.4	 0	 100	 6	
30.00	 0.4	 30	 70	 6	




CUR	 20	 	 CAD	 Medium
IS	 4500	 DP	 100	
TEM	 300	 EP	 10	





GS2	 20	 CXP 10
ihe	 ON	 	 	
Transitions:	
Analyte	 Q1	mass	(Da) Q3	mass	(Da)	 Dwell	(ms)	




endogenous	SA	PI‐aldehyde	product 713.38	 439.3	 50	
17:0‐20:4	PI‐aldehyde	product	 699.4	 425.3	 50	
	
2.2.7 Measurement of PI3P and PI4P  










Time	(min)	 Flow	rate		(ul/min)	 %A	 %B	 Curve	
0	 10	 30	 70	 	
5	 10	 30 70 6	
10	 10	 22	 78	 1	
35	 10	 22	 78	 6	
36	 10	 0 100 6	
45	 10	 0	 100	 6	









Analyte	 Q1	mass	(Da)	 Q3	mass	(Da)	 Dwell	(ms)	































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































in	10	week	[Ptenflox/flox, PbCre-/-] (‘WT’)	and	[Ptenflox/flox, PbCre+/-] (‘PTEN‐KO’)	prostate	
Figure 8.1 Model of cancer progression in mouse prostate 
During tumorigenesis, normal prostate epithelium undergoes hyperplastic growth to progress through high‐
grade prostatic intraepithelial neoplasia (PIN) into cribriform PIN ‐ considered as prostate carcinoma in situ. In 
later stages of disease progression, cancer cells cross the barrier of smooth muscle cells, which leads to 
development of microinvasive adenocarcinoma and effectively invasive carcinoma. Adapted from (Iwata, Schultz 
et al. 2010).  
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biopsies	by	HPLC‐ESI	MS/MS	(Figure	8.2).	Epithelium‐specific	Pten	deletion	in	prostate	
led	to	an	~25	fold	increase	in	PI(3,4,5)P3	compared	to	the	WT	condition.	More	
surprisingly,	we	noted	a	substantial	accumulation	of	PI(3,4)P2	in	PTEN‐KO	prostate,	
with	levels	of	this	phosphatidylinositol	lipid	reaching	~50%	of	PI(4,5)P2	(Figure	8.2A).	
This	was	an	unexpected	observation,	especially	in	the	context	of	our	previous	studies	in	
Mcf10a	cells,	where	EGF‐stimulated	PI(3,4)P2	levels	in	PTEN‐KO	cells	never	exceed	5%	
with	respect	to	PI(4,5)P2.	This	immediately	suggested	PTEN	may	have	a	highly	
significant	pathophysiological	role	in	regulating	not	only	PI(3,4,5)P3,	but	also	PI(3,4)P2	
levels	in	mouse	prostate.		
8.2.2 The impact of deleting PTEN and INPP4B in mouse prostate 
In	order	to	better	understand	the	function	of	PTEN	and	INPP4B	in	PI(3,4)P2	
homeostasis	in	mouse	prostate,	we	generated	a	series	of	tissue	cryosections	from	mice	
of	different	genetic	background	and	at	different	ages.	In	pilot	experiments,	freshly	
dissected	prostates	from	12	week	WT	or	PTEN‐KO	animals	were	fixed	in	
paraformaldehyde	and	after	incubation	in	sucrose,	slowly	frozen	in	the	embedding	
Figure 8.2 Phosphatidylinositol lipid levels in mouse prostate measured 
by HPLC‐ESI MS/MS 
(A) HPLC‐ESI MS/MS quantitation of the indicated phosphatidylinositol 
lipids in prostate biopsies taken from WT or PTEN‐KO mice at 10 weeks of 
age; the data are means  SD from the analysis of 3 mice in each 
genotype. (B) Representative chromatograms showing levels of PIP2 in 
prostate biopsies taken from WT or PTEN‐KO mice at 10 weeks of age. 
Experiment was performed in Takehiko Sasaki’s laboratory, Akita 
University. 
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medium	(refer	to	Methods	section	for	more	detail).	Embedded	prostates	were	then	
sectioned	to	give	12	μm	specimens,	followed	by	labelling	of	representative	sections	with	
anti‐PI(3,4)P2	antibody	and	a	nuclear	stain	‐	Hoechst	(Figure	8.3).	The	acini	in	WT	
prostate	looked	normal,	with	a	clear	layer	of	luminal	cells	at	the	periphery	and	no	
detectable	PI(3,4)P2‐specific	staining.	In	contrast,	cryosections	from	PTEN‐KO	prostate	
were	more	heterogeneous.	Some	areas	displayed	characteristics	of	WT	sections,	which	
was	probably	due	to	lack	of	Cre	recombinase	activity	and	resulting	from	this,	differences	
in	disease	progression	between	different	lobes.	These	‘normal’	areas	of	PTEN‐KO	
prostate	contrasted	with	neighbouring	regions,	in	which	very	intense	PI(3,4)P2	staining	
correlated	with	acini	showing	signs	of	high	grade	PIN.	These	results	were	the	first	in	vivo	
demonstration	of	aberrant	growth	that	correlated	with	PI(3,4)P2‐rich,	prostatic	
epithelial	cells	lacking	PTEN	expression.			
These	initial	observations	were	a	motivation	to	extend	the	study	and	compare	
PTEN’s	role	in	mouse	prostate	versus	that	of	INPP4B.	To	achieve	this,	we	used	an	
analogous	approach	and	prepared	cryosections	from	16	week	mice	with	four	different	
genetic	backgrounds:	[Ptenflox/flox,	PbCre‐/‐]	(‘WT’),	[Ptenflox/flox,	PbCre+/‐]	(‘PTEN‐KO’),	
[Ptenflox/flox,	PbCre‐/‐,	Inpp4b‐/‐]	(‘INPP4B‐KO’)	and	[Ptenflox/flox,	PbCre+/‐	Inpp4b‐/‐]	(‘PTEN‐
INPP4B‐KO’)	mice.	Two	adjacent	sections	were	chosen	per	condition:	the	first	was	
labelled	with	anti‐PI(3,4)P2	antibody	and	the	second	was	subject	to	standard	H&E	
Figure 8.3 PI(3,4)P2 staining in 12 week mouse prostate cryosections 
An example of Hoechst and anti‐PI(3,4)P2 stained sections of prostates taken from  WT and PTEN‐KO mice at 12 
weeks of age. White arrows indicate normal acini and yellow arrows indicate regions in the prostate where acini 
exhibit HG‐PIN. Images are confocal sections of a 12 μm specimen and scale bars represent 0.2 mm. 
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staining	for	histopathological	examination	(Figure	8.4A).	Analysis	of	
immunofluorescence	images	from	WT	and	INPP4B‐KO	prostates	showed	no	significant	
difference	in	PI(3,4)P2	staining.	Conversely,	prostate	sections	from	PTEN‐KO	and	PTEN‐
INPP4B‐KO	mice	showed	very	high	accumulation	of	PI(3,4)P2	in	the	acini,	with	signal	
intensity	indiscernible	between	the	two	genotypes.	Moreover,	PI(3,4)P2	signal	maxima	
Figure 8.4 The impact of deleting Pten and Inpp4b in mouse prostate 
(A) H&E, Hoechst and anti‐PI(3,4)P2 stained sections of prostates taken from WT; PTEN‐KO; INPP4B‐KO or PTEN‐
INPP4B‐KO mice at 16 weeks of age (scale bar represents 1 mm). (B) Some areas of PTEN‐KO and PTEN‐INPP4B‐
KO sections are shown at higher magnification (scale bar represents 0.2 mm) and levels of anti‐PI(3,4)P2 staining 
are represented on the pseudo‐colour scale shown; examples of the tips of growing acini are indicated by white 
arrows. The images shown are typical of 3 prostate sections analysed from 3 mice in each genotype. Seminal 
vesicles (SV), anterior (A), dorsolateral (DLP) and ventral (V) lobes of the prostate are indicated by black arrows. 
(C) A representative Western blot is shown describing the relative expression of INPP4B and PTEN in the indicated 
mouse tissues (estimated 20 μg total protein loaded per lane) and human Mcf10a cell clones (15 μg total protein 
loaded per lane). This experiment was repeated 3 times with similar results. Note: in PTEN‐KO prostates, Cre 
expression and hence PTEN deletion is restricted to prostate epithelial cells which represent only approx 70% of 
total cellular content. Western Blot analysis performed by Tamara Chessa, Babraham Institute. 
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in	these	two	genotypes	seemed	to	localize	at	the	tips	of	fast	proliferating	acini	(Figure	
Figure	8.4B).		
The	lack	of	effect	of	Inpp4b	depletion	on	PI(3,4)P2	levels	and	a	negligible	difference	
between	PTEN	and	PTEN‐INPP4B‐KO	genotypes,	implied	that	PTEN	may	be	the	major	
PI(3,4)P2	phosphatase	in	mouse	prostate.	To	test	this,	we	measured	protein	levels	of	
PTEN	and	INPP4B	in	mouse	prostate	and	compared	these	to	expression	levels	in	other	
mouse	organs	and	Mcf10a	cells	(Figure	8.4C).	The	results	indicate	that	the	protein	level	
of	INPP4B	in	mouse	prostate	is	very	low,	which	would	explain	why	loss	of	Pten,	and	not	
Inpp4b,	has	a	very	large	impact	on	PI(3,4)P2	accumulation	in	this	organ.	
8.2.3 Pathophysiological significance of PTEN deletion in mouse prostate  
Phosphatidylinositol	lipid	analysis	in	mouse	prostate	provided	us	with	an	insight	
into	the	molecular	mechanisms	that	regulate	PI(3,4)P2	levels	in	this	tissue.	However,	the	
more	challenging	task	was	to	correlate	these	observations	with	a	pathophysiological	
outcome,	in	situations	when	the	PI3K	pathway	becomes	deregulated.	For	this,	similar	to	
previous	studies	in	Mcf10a	cells,	we	tried	to	evaluate	the	levels	of	AKT	phosphorylation	
resulting	from	PI(3,4)P2	phosphatase	deletion	in	mouse	prostate.	Staining	of	WT	
prostate	with	anti‐phospho‐473Ser‐AKT	gave	a	weak	signal,	which	substantially	
Figure 8.5 PI(3,4)P2 and pAKT levels in 16 week mouse prostate  
An example of anti‐phospho‐473Ser‐AKT and anti‐PI(3,4)P2 stained sections of prostates taken from  [PTENflox/flox, 
PbCre‐/‐] (‘WT’) and [PTENflox/flox, PbCre+/‐ INPP4B‐/‐] (‘PTEN‐INPP4B‐KO’) mice at 16 weeks of age (12mm sections). 
Some areas in anterior prostate of WT and PTEN‐INPP4B‐KO wide field images are shown at higher 
magnification, to show localisation of antibody staining. Scale bar represents 1 mm. 
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increased	in	analogous	staining	of	PTEN‐INPP4B‐KO	prostate	(Figure	8.5).	Significantly,	
increased	phosphorylated‐AKT	levels	overlapped	with	increased	anti‐PI(3,4)P2	labelling	
in	this	genotype.	Although	473Ser‐AKT	is	not	an	exclusive	PI(3,4)P2	marker,	it	was	a	good		
indication	that	increased	AKT	activity	is	indeed	observed	in	the	epithelial	cells	which	
undergo	hyperplastic	growth	and	are	a	hallmark	of	the	disease	state	that	evolves	in	
mouse	prostate.				
Histopathology	is	one	of	the	most	utilised	microscopy	techniques	for	comparative	
examination	of	tissue	biopsies	and	an	important	diagnostic	tool	used	in	oncology	and	
other	areas	of	medicine.	Labelling	methods	vary	depending	on	the	cell	type	and	subject	
of	investigation,	but	the	most	broadly	used	among	them	is	a	classical	haematoxylin	and	
eosin	(H&E)	staining.	In	order	to	evaluate	disease	progression	in	mouse	prostates	with	
deleted	Pten,	we	performed	H&E	staining	of	prostate	cryosections	from	16	week	mice	of	
four	different	genotypes,	i.e.	WT,	PTEN‐KO,	INPP4B‐KO	and	PTEN‐INPP4B‐KO.	We	also	
established	a	collaboration	with	Sergio	Felisbino	from	the	University	of	Sao	Paulo,	to	
gain	an	independent	and	unbiased	opinion	about	the	changes	that	occur	in	genetically	
modified	mouse	prostates.	Normal	mouse	prostate	is	characterised	by	acini	surrounded	
by	a	continuous	layer	of	smooth	muscle	cells	and	dispersed	in	the	connective	tissue	of	
the	stroma	(Figure	8.6).	In	such	tissue,	PI(3,4)P2	was	virtually	undetectable	by	the	anti‐
PI(3,4)P2	antibody.	Acini	in	INPP4B‐KO	prostate	sections	showed	no	signs	of	
hyperplasia	and,	to	the	level	of	confidence	provided	by	H&E	and	anti‐PI(3,4)P2	staining,	
Figure 8.6 H&E staining and PI(3,4)P2 levels in WT mouse prostate 
H&E, Hoechst and anti‐PI(3,4)P2 stained sections of prostates taken from [PTENflox/flox, PbCre‐/‐](‘WT’) mice at 
16 weeks of age. In the H&E panel, yellow arrows indicate smooth muscle cell layer, black arrows indicate luminal 
cells of the acini and asterisks indicate cells of the stroma. The images shown are typical of 3 prostate sections 
analysed from 3 mice in each genotype. 
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they	did	not	differ	significantly	from	WT	prostates	(data	not	shown).	Deletion	of	Pten,	on	
the	other	hand,	had	a	significant	impact	on	mouse	prostate	morphology.	
Hyperproliferative	growth	of	acinar	epithelial	cells	was	accompanied	by	co‐evolution	of	
reactive	stroma	and,	in	some	cases,	gradual	infiltration	of	immune	cells.	This,	and	the	
apparent	loss	of	the	smooth	muscle	cell	layer	around	acini,	were	indications	of	initial	
stages	of	microinvasion	occurring	in	the	prostate	from	PTEN‐KO	mice	(Figure	8.7).	
Subsequent	histopathological	examination	of	prostates	from	PTEN‐INPP4B‐KO	mice	led	
to	similar	observations.	Notably,	prostates	from	PTEN‐KO	and	PTEN‐INPP4B‐KO	mice	
showed	elevated	levels	of	PI(3,4)P2	which	strongly	correlated	with	acini	in	the	lobes	
characterised	by	most	pronounced	disease	progression.	
Figure 8.7 H&E staining and PI(3,4)P2 levels in PTEN and PTEN‐INPP4B‐KO mouse prostate 
 H&E, Hoechst and anti‐PI(3,4)P2 stained sections of prostates taken from [PTENflox/flox, PbCre+/‐](‘PTEN‐KO’) and 
[PTENflox/flox, PbCre+/‐ INPP4B‐/‐] (‘PTEN‐INPP4B‐KO’) mice at 16 weeks of age (scale bar represents 69 μm). In the 
H&E panel and insets, arrows indicate position of hyperproliferative epithelium and asterisks indicate reactive 
stroma and loss of the smooth muscle cell layer. In the Hoechst/PI(3,4)P2 panel, yellow arrows indicate high 
PI(3,4)P2 levels in the acini that correspond to the insets in the H&E images. The images shown are typical of 3 
prostate sections analysed from 3 mice in each genotype. Histopathological expertise obtained from Sergio 
Felisbino, University of Sao Paulo. 
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8.2.4 Role of PTEN as a PI(3,4)P2 phosphatase in human prostate cancer cell lines 
PTEN	deregulation	is	one	of	the	primary	molecular	drivers	of	prostatic	neoplasia	in	
men,	with	genetic	abnormalities	detected	in	nearly	1	in	3	cases	of	advanced	primary	
tumours	(Wang,	Gao	et	al.	2003).	Due	to	its	haploinsufficient	character,	consequences	of	
loss	of	one	functional	PTEN	allele	are	clearly	manifested	by	elevated	AKT	
phosphorylation.	Human	prostate	cancer	cell	lines	have	been	extensively	used	as	tools	
to	study	prostate	cancer	biology,	especially	in	the	context	of	functional	overlap	between	
PI3K/AKT	and	AR	signalling	axes.	Unlike	in	mice,	INPP4B	has	an	important	role	in	
human	prostate	and	its	expression	seems	to	be	androgen‐regulated	(Hodgson,	Shao	et	
al.	2011).		
We	chose	a	panel	of	human	prostate	cancer	cell	lines	and	examined	the	impact	of	
INPP4B	or	PTEN	absence	on	the	EGF‐	or	IGF1‐stimulated	accumulation	of	PI(3,4,5)P3	
and	PI(3,4)P2	(Figure	8.8A,	B).	In	parallel,	we	performed	Western	blot	analysis	to	assess	
INPP4B	and	PTEN	expression	in	these	cells	(Figure	8.8C).	EGF	and	IGF1	stimulated	
PI(3,4,5)P3	accumulation	in	BPH1	(‘WT’	control)	and	DU145	(‘INPP4B‐KO’)	cells,	but	did	
not	lead	to	a	detectable	increase	in	PI(3,4)P2.	Cells	lacking	PTEN,	i.e.	LNCaP,	LNCaP95	
and	PC3,	showed	elevated,	basal	PI(3,4,5)P3	levels	and	accumulated	significant	amounts	
of	both	PI(3,4,5)P3	and	PI(3,4)P2	in	response	to	EGF.	Interestingly,	the	kinetics	and	
relative	amounts	of	phosphatidylinositol	lipids	differed	between	the	three	‘PTEN‐KO’	
cell	lines,	which	may	be	related	to	availability	and/or	activation	of	5‐phosphatases	in	
each	cell	type	or	additional	factors	(e.g.	mutations),	which	are	common	in	transformed	
cells.	Surprisingly,	IGF1	stimulation	did	not	result	in	significant	increases	in	PI(3,4)P2	or	
PI(3,4,5)P3	in	‘PTEN‐KO’	cells.	This	phenomenon	may	be	partly	explained	by	negative	
feedback	within	the	IGF‐signalling	pathway	caused	by	hyperactivation	of	the	PI3K	
pathway	upon	PTEN	deletion	–	an	observation	made	in	a	parallel	project	in	our	lab.				
Unfortunately	we	did	not	find	a	prostate	line	in	which	both	PTEN	and	INPP4B	were	
mutated.	
	
	 	
PTEN regulates the accumulation of PI(3,4)P2 in mouse prostate 
 
148 
	
	
Figure 8.8 PI(3,4,5)P3 and PI(3,4)P2 in prostate cancer cells 
(A) PI(3,4,5)P3 and (B) PI(3,4)P2 levels in human prostate cancer cell lines starved and then stimulated with EGF 
(10ng/ml) or IGF1 (50ng/ml) for 0, 1, 5 or 15 min. Phosphatidylinositol lipids were analysed by HPLC‐ESI MS/MS 
using a C4 or C18 column for measurement of  PI(3,4,5)P3 and PI(3,4)P2, respectively. Data are means ± SD of at 
least two independent experiments. (C) Western blot showing relative expression of INPP4B, PTEN and beta‐COP 
in the indicated human prostate cancer cell lines (20mg total protein loaded per lane). Western blot analysis was 
performed by Tamara Chessa, Babraham Institute. 
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8.3 	Discussion 
We	demonstrated	here	a	critical	role	for	PTEN	in	controlling	cellular	processes	that	
underpin	normal	prostate	development	and	function.	By	using	a	conditional	mouse	
knock‐out	model,	we	were	able	to	restrict	our	observations	to	Pten‐null,	prostatic	
epithelial	cells	and	exclude	other	systemic	effects.	Importantly,	PI(3,4)P2	levels	were	
significantly	elevated	in	PTEN‐KO	prostates	from	early	stages	of	tumour	development	
(10	weeks)	to	a	pre‐invasive	state	(16	weeks)	and	we	were	able	to	detect	these	levels	
reliably	by	HPLC‐ESI	MS/MS	as	well	as	using	an	anti‐PI(3,4)P2	antibody.	We	were	
surprised	by	the	high	accumulation	of	PI(3,4)P2,	reaching	almost	equivalent	levels	to	
PI(4,5)P2	in	prostates	from	10	week	PTEN‐KO	animals.	Since	then,	we	have	also	
observed	comparably	high	levels	of	PI(3,4)P2	accumulation	in	PTEN‐KO	prostate	
organoids	grown	in	acidic	pH	for	extended	periods	of	time	(data	not	shown).	Further,	we	
demonstrated	very	low	expression	of	INPP4B	in	mouse	prostate	compared	to	other	mice	
tissues	or	Mcf10a	cells	with	comparable	expression	of	PTEN.		
Histopathological	examination	of	mouse	prostate	sections	revealed	that	elevated	
PI(3,4)P2	marks	the	tips	of	growing	acini	and	acini	which	show	early	stages	of	
microinvasion.	Finally,	we	correlated	high	PI(3,4)P2	levels	with	regions	in	mouse	
prostate	with	enhanced	phospho‐473Ser‐AKT	‐	a	marker	suggested	to	positively	correlate	
with	high	Gleason	grade	in	patients	with	advanced	prostate	cancer	(Ayala,	Thompson	et	
al.	2004).	
Prostate	cancer	cell	lines	with	reported	PTEN	deletion	have	been	characterised	by	
hyperactivation	of	AKT	(Nacerddine,	Beaudry	et	al.	2012).	We	demonstrated	that	cells	
lacking	PTEN,	but	not	INPP4B,	accumulate	significant	levels	of	PI(3,4,5)P3	and	PI(3,4)P2	
in	response	to	stimulation	with	EGF.	Unfortunately,	we	were	unable	to	identify	a	
prostate	cancer	cell	line	with	low	INPP4B	expression	in	addition	to	a	PTEN‐null	
background	(our	best	candidate,	the	NCI	H660	cell	line,	expressed	~30%	of	INPP4B	
relative	to	‘WT’	cells).	
Overall,	our	analysis	of	mouse	prostate	was	consistent	with	our	observations	in	
Mcf10a	cells.	Conditions	in	which	both	PTEN	and	INPP4B	are	absent,	mouse	PTEN‐KO	
prostate	or	PTEN‐INPP4B‐KO	Mcf10a	cells,	result	in	substantial	accumulation	of	
PI(3,4)P2.	In	contrast	to	mouse	prostate,	human	prostate	cell	lines	express	significant	
levels	of	INPP4B.	However,	several	studies	have	now	shown	that	advanced,	androgen‐
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ablation‐resistant	prostate	cancer	is	characterised	by	a	high	incidence	of	PTEN	mutation	
and	relatively	low	levels	of	INPP4B	expression.	This	has	obvious	implications	for	a	
potential	role	for	PI(3,4)P2	in	tumorigenesis	and	this	is	discussed	further	in	the	next	
Chapter.	
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Chapter 9 General discussion 
Since	the	initial	discovery	of	PTEN	in	the	late	90s,	our	understanding	of	its	central	
role	in	modulating	physiological	processes	driven	by	class	I	PI3K	signalling	has	
significantly	advanced.	Although	the	intellectual	link	between	PTEN,	PI(3,4,5)P3	and	
AKT	remains	fully	justifiable,	the	work	presented	in	this	dissertation	describes	PTEN	as	
a	dual	PI(3,4,5)P3/PI(3,4)P2	lipid	phosphatase,	which	not	only	emphasizes	its	
importance	in	cellular	homeostasis	but	raises	an	immediate	question	about	the	
overlapping/divergent	functions	of	these	two	phosphatidylinositol	lipids.	Inevitably,	
time	limitations	of	this	project	restricted	our	ability	to	explore	some	of	the	observations	
that	emerged	during	its	course,	hence,	several	important	questions	still	need	resolving.	
Nevertheless,	I	hope	that	our	initial	attempts	to	characterise	PTEN	as	a	physiological	
PI(3,4)P2	3‐phosphatase	in	Mcf10a	cells	and	mouse	prostate	will	stimulate	a	scientific	
discussion	and	create	a	driving	force	for	future	studies	to	fully	appreciate	PTEN’s	
importance	as	a	tumour	suppressor.	
The	newly	developed	HPLC‐ESI	MS/MS	method	for	measuring	two	regioisomers	‐	
PI(3,4)P2	and	PI(4,5)P2	‐	was	instrumental	in	performing	the	core	experiments	of	this	
project	and	in	demonstrating	PTEN’s	direct	role	as	a	PI(3,4)P2	phosphatase.	However,	its	
restriction	to	the	measurement	of	the	C38:4	molecular	species	of	these	lipids,	together	
with	the	need	for	a	separate	method	to	measure	PI(3,4,5)P3,	are	significant	limitations.	
The	C38:4	species	is	the	most	abundant	form	of	inositol	lipids	in	primary	mammalian	
cells	(Clark,	Anderson	et	al.	2011,	Anderson,	Juvin	et	al.	2016),	but	recent	papers	have	
started	to	suggest	that	the	acyl	composition	of	these	lipids	may	be	under	tight	regulation	
(Naguib,	Bencze	et	al.	2015).	Furthermore,	analysing	these	lipids	in	other	eukaryotes	
would	require	significant	further	development	of	the	method	described	here.	This	
method	was	also	unable	to	sufficiently	resolve	PI(3,5)P2	from	PI(4,5)P2,	or	the	
regioisomers	of	PIPs	(PI3P,	PI4P,	PI5P)	to	allow	their	measurement	in	cell	extracts.	
Thus,	future	efforts	should	focus	on	developing	a	universal	mass	spectrometry	method,	
one	that	would	allow	quantification	of	the	eight	phosphatidylinositol	lipid	members,	
irrespective	of	their	headgroup	or	acyl	chain	characteristics.		
	The	HPLC‐ESI	MS/MS	method	gave	a	much	higher	value	for	PI(3,4)P2	in	basal	
Mcf10a	cells	than	parallel	labelling	studies	with	[33P]Pi.	We	do	not	understand	the	
reason	for	this	discrepancy,	but	a	slowly	turning	over	pool	of	PI(3,4)P2	or	some	form	of	
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mass	contaminant	seem	the	most	plausible	explanations.	Labelling	cells	to	equilibrium	
with	radiolabelled	and/or	isotope	enriched	inositol	would	seem	to	be	the	next	logical	
step	to	resolving	this.	
Our	studies	in	human	mammary	epithelial	cells	(Mcf10a),	prostate	cancer	cell	lines	
and	mouse	prostate	supported	previous	observations	suggesting	substantial	functional	
redundancy	exists	amongst	the	lipid	phosphatases	that	are	a	result	of	complex	
regulatory	mechanisms	which	are	organism‐,	cell‐	and	stimulus‐specific.	LPS‐activated	B	
cells	from	Ship1‐/‐	mice	were	shown	to	express	SHIP2	as	a	compensatory	mechanism	to	
antagonise	BCR‐mediated	AKT	phosphorylation	via	interaction	with	the	tyrosine‐
phosphorylated	ITIM	motifs	of	cytosolic	FcγRIIB	tails	(Brauweiler,	Tamir	et	al.	2001).	In	
contrast,	human	platelets	seem	to	rely	on	SHIP1’s	activity	to	dephosphorylate	
PI(3,4,5)P3,	with	a	marginal	contribution	from	SHIP2	and	PTEN	(Giuriato,	Pesesse	et	al.	
2003).	Keeping	this	in	mind,	our	inability	to	define	a	group	of	5‐phosphatases	with	a	
dominant	role	in	the	dephosphorylation	of	class	I	PI3K‐generated	PI(3,4,5)P3	in	EGF‐
stimulated	Mcf10a	cells	was	still	surprising.	On	the	other	hand,	PI(3,4,5)P3	levels	
generated	in	EGF‐stimulated	[PTEN‐SHIP2‐KO,	INPP4A/B‐KD]	cells	represent	a	highly	
abnormal	situation,	where	phosphatases	may	become	enrolled	in	the	dephosphorylation	
of	PI(3,4,5)P3	that	would	not	normally	contribute	under	more	physiological	
circumstances.	This	is	precisely	what	has	previously	been	proposed	to	be	the	role	of	
INPP4B	in	the	dephosphorylation	of	PI(3,4,5)P3	in	PTEN‐deficient	mouse	thyroid	(Kofuji,	
Kimura	et	al.	2015),	although	we	observed	no	such	role	for	this	protein	in	Mcf10a	cells.	
Our	results	describing	PTEN	as	a	direct	PI(3,4)P2	phosphatase	has	evolved	the	
current	perception	of	its	role	in	the	context	of	class	I	PI3K	signalling.	There	are	two	main	
reasons	why	this	role	may	have	been	under‐appreciated	in	the	past.	Firstly,	it	is	difficult	
to	study	PI(3,4)P2,	a	secondary	product	of	class	I	PI3K	activity,	decoupled	from	
transiently	generated	PI(3,4,5)P3.	Hence,	arguments	such	as	increased	flux	through	
PI(3,4,5)P3	5‐dephosphorylation	were	probably	the	most	intuitive	explanation	in	cases	
where	elevated	PI(3,4)P2	and	PI(3,4,5)P3	levels	were	observed	in	cells	lacking	PTEN	
activity.	Secondly,	whilst	PI(3,4)P2	was	recognised	as	a	potential	substrate	for	PTEN	in	
early	in	vitro	experiments	(Maehama	and	Dixon	1998),	the	most	sophisticated	analyses	
suggested	it	was	a	very	poor	substrate	compared	to	PI(3,4,5)P3	(McConnachie,	Pass	et	al.	
2003).	We	don’t	yet	understand	why	PTEN	was	such	an	effective	PI(3,4)P2	3‐
phosphatase	in	our	Mcf10a	cytosol	assays,	but	a	clue	may	be	the	inclusion	of	substantial	
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amounts	of	PI(4,5)P2	in	all	of	our	assays,	which	is	an	important	co‐factor	for	PTEN	and	
which	would	be	autologously	generated	from	PI(3,4,5)P3,	but	not	PI(3,4)P2,	in	assays	
containing	only	these	substrates.	A	strategy	to	circumvent	the	coupling	of	PTEN’s	effects	
on	PI(3,4,5)P3	and	PI(3,4)P2,	would	be	to	generate	a	PTEN	mutant	capable	of	
hydrolysing	PI(3,4,5)P3	but	not	PI(3,4)P2.	In	this	regard,	it	would	also	be	extremely	
interesting	to	evaluate	whether	specific	missense	mutations	in	PTEN	observed	in	cancer	
or	overgrowth	syndromes	differ	in	their	relative	abilities	to	hydrolyse	PI(3,4)P2	versus	
PI(3,4,5)P3.	
Our	results	draw	into	focus	the	potential	role	for	PI(3,4)P2	as	a	signalling	molecule	in	
its	own	right	and	its	contribution	to	the	phenotypes	observed	when	PTEN	function	is	
impaired.	The	recently	described	class	I	PI3K‐mediated	endocytic	recycling	of	agonist‐
activated	RTKs	and	GPCRs	(i.e.	endophilin‐specific	‘FEME’,	see	Introduction)	is	an	
example	of	a	physiological	process	that	depends	on	cellular	PI(3,4)P2	(Boucrot,	Ferreira	
et	al.	2015).	Here,	INPP4A/B	suppression	in	cells	was	shown	to	increase	endophilin‐
positive	endosomes/lysosomes	and	it	would	be	interesting	to	carefully	test	PTEN’s	
contribution	to	this	process,	particularly	given	PTEN’s	best	characterised	roles	as	a	lipid	
phosphatase	acting	on	PI(4,5)P2‐rich	plasma	membranes.	This	would	also	help	put	into	
perspective	the	level	of	redundancy	between	PI(3,4)P2‐specific	phosphatases	‐	a	
question	that	we	did	not	answer	exhaustively	during	this	project.				
The	interaction	between	PH	domain‐containing	AKT	and	PI(3,4,5)P3/PI(3,4)P2	is	an	
obligatory	step	to	trigger	kinase	catalytic	activity	and	many	experiments	have	shown	
that	chemical	inhibition	of	class	I	PI3K	terminates	AKT‐driven	processes.	However,	the	
precise	relative	contribution	of	PI(3,4,5)P3	versus	PI(3,4)P2	to	the	activation	of	AKT	in	
any	given	pathophysiological	context	is	still	unclear.	Further,	the	interaction	between	
scaffolding	proteins	like	LPD,	TKS5	or	SNX9	and	PI(3,4)P2,	is	only	one	of	several	stages	
during	the	assembly	of	multicomponent	protein‐complexes	in	the	vicinity	of	the	plasma	
membrane,	which	makes	it	very	difficult	to	isolate	the	specific	contribution	that	
PI(3,4)P2	makes	and	hence	its	indispensability	to	the	physiological	process.	
Nevertheless,	PI(3,4)P2	is	starting	to	emerge	as	an	important	modulator	of	processes	
which	influence	cellular	motility,	signalling	efficiency	and	tumour	progression.	Our	
studies	show	a	strong	correlation	between	EGF‐stimulated	PI(3,4)P2	formation,	which	in	
Mcf10a	cells	accumulates	as	a	consequence	of	combined	deletion	of	its	two	direct	
phosphatases,	PTEN	and	INPP4B,	and	an	increased	number	of	gelatin‐degrading	
General discussion 
 
154 
	
invadopodia.	Whilst	additional	experiments	are	required	to	relate	this	observation	to	
the	TKS5‐PI(3,4)P2	interaction	described	in	the	literature,	our	experiments	suggest	that	
an	invasive	phenotype	can	be	induced	in	Mcf10a	cells	driven	by	the	presence	of	
PI(3,4)P2	and	thus	implies	a	new	potential	role	for	the	PTEN	tumour	suppressor.	The	
involvement	of	PI(3,4)P2	in	the	class	I	PI3K‐mediated	invasive	potential	of	mutated	
Mcf10a	cells	is	also	in	line	with	the	most	recent	work	performed	in	breast	cancer	cells	
(Fukumoto,	Ijuin	et	al.	2017).	Fukumoto	et	al.	described	SHIP2	as	a	‘phenotypic	switch’,	
which	when	supressed,	transforms	highly	motile,	lamellipodia‐forming	MDA‐MB‐231	
cells	into	cells	with	increased	number	of	mature	focal	adhesions	and	extended	surface	
area.	The	invasive	phenotype	of	‘native’	MDA‐MB‐231	cells	was	shown	to	depend	on	
class	I	PI3K	activity,	combined	with	SHIP2’s	generation	of	PI(3,4)P2.	Interestingly,	PTEN	
knock‐down	did	not	affect	focal	adhesion	formation	but	led	to	decreased	cell	size	and	
increased	cell	penetration	through	matrigel,	indicating	enhanced	invasive	character	
compared	to	control	MDA‐MB‐231	cells.	Further,	cells	with	combined	suppression	of	
PTEN	and	SHIP2,	i.e.	cells	with	impeded	PI(3,4,5)P3	hydrolytic	activity,	showed	
decreased	matrigel‐penetration	ability,	similar	to	SHIP2‐KD	cells.	In	light	of	this	recent	
work,	it	would	be	interesting	to	test	the	effect	of	SHIP2	depletion	on	Mcf10a’s	ability	to	
form	invadopodia,	especially	in	the	[PTEN‐KO,	INPP4B‐KD]	mutant	cells,	where	SHIP2	
deletion	had	a	negligible	effect	on	total	cellular	PI(3,4)P2	levels.	Finally,	future	
experiments	should	focus	on	validating	the	molecular	mechanisms	that	link	the	
phosphatidylinositol	lipid	PI(3,4)P2,	PTEN	and	cellular	invasiveness	in	the	in	vivo	setting	
of	invadopodia	formation	by	cancer	cells.	
Tumourigenesis	can	be	described	as	process	in	which	normal	cells	escape	tight	
regulatory	mechanisms	controlling	proliferation	and	programmed	cell	death	through	
acquired	mutations.	Unrestrained	cellular	growth	and	division,	as	well	as	survival	under	
limiting	nutrient	conditions	due	to	reprogrammed	metabolic	pathways,	are	some	of	the	
characteristics	of	transformed	cells.	It	is	therefore	perhaps	unsurprising	that	a	powerful	
tumour	suppressor	such	as	PTEN	turned	out	to	be	a	direct	antagonist	of	class	I	PI3K‐
signalling.	Despite	this,	the	differential	susceptibility	of	tissues	to	PTEN‐driven	
carcinogenesis	and	the	complex	mechanisms	that	underpin	PTEN’s	expression	and	
activity	are	the	subject	of	an	ongoing	debate.	PTEN’s	function	as	the	major	phosphatase	
regulating	PI(3,4)P2	levels	in	mouse	prostate	and	PI(3,4)P2‘s	correlation	with	the	
regions	of	most	advanced	disease	progression	(i.e.	exhibiting	high	grade	PIN	and	in	
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some	cases	the	first	signs	of	microinvasion),	substantiated	our	previous	findings	in	
Mcf10a	cells	and	provoked	a	consideration	about	PI(3,4)P2‘s	role	in	tumourigenesis.	
Advanced	cancers	are	characterised	by	outgrowth	beyond	the	initiation	site	and/or	by	
their	potential	to	metastasize.	The	potential	for	INPP4B	to	act	as	a	conditional	tumour	
suppressor	in	mouse	thyroid	was	demonstrated	by	crossing	mice	lacking	both	alleles	of	
Inpp4b	with	mice	lacking	one	allele	of	Pten	(Kofuji,	Kimura	et	al.	2015,	Li	Chew,	Lunardi	
et	al.	2015).	Our	results	indicating	both	INPP4B	and	PTEN	can	act	in	a	partially	
redundant	manner	in	the	dephosphorylation	of	PI(3,4)P2	provides	a	potential	
explanation	for	these	observations.	Further,	the	importance	of	INPP4B	as	a	tumour	
suppressor	in	humans	is	supported	by	studies	showing	that	loss	of	INPP4B	expression	
correlated	with	advanced	breast	and	poorly‐prognosing	ovarian	cancer	(Gewinner,	
Wang	et	al.	2009,	Fedele,	Ooms	et	al.	2010).	Moreover,	coincidental	downregulation	at	
the	gene	and/or	protein	level	of	PTEN	and	INPP4B	was	revealed	by	the	analysis	of	
human	thyroid	and	endometrial	cancer	databases	(Kofuji,	Kimura	et	al.	2015).	In	human	
prostate,	loss	of	expression	of	PTEN	or	INPP4B	has	been	associated	with	poor	prognosis	
in	advanced	tumours	but	no	significant	correlation	between	these	two	events	has	been	
reported	(Rynkiewicz,	Fedele	et	al.	2015).	However,	due	to	INPP4B’s	transcriptional	
regulation	downstream	of	androgen	receptor	signalling,	the	relationship	between	PTEN	
and	INPP4B,	and	their	potential	impact	on	PI(3,4)P2	levels	in	patients	subject	to	
androgen‐ablation	therapy	is	more	complex	(Hodgson,	Shao	et	al.	2011).	Considering	
these	findings,	one	could	hypothesize	that	in	advanced	tumours	a	hyperproliferative	
phenotype	co‐exists	with	an	activated	invasive	phenotype	due,	at	least	in	part,	to	
enhanced	PI(3,4)P2	accumulation.	This	is	especially	interesting	in	light	of	SHIP2’s	
control	of	the	invasive	phenotype	in	MDA‐MB‐231	cells	(discussed	earlier	in	this	
Chapter	(Fukumoto,	Ijuin	et	al.	2017))	and	emerging	reports	that	postulate	a	correlation	
between	SHIP2’s	overexpression	and	poor	outcome	in	metastatic	breast	cancer	(Prasad,	
Tandon	et	al.	2008).	If	followed	up	in	future	studies,	this	may	bring	a	new	functional	
significance	to	the	5‐dephosphorylation	route	of	PI(3,4,5)P3	removal	and	specific	5‐
phosphatase’s	role	within	it.	With	this	in	mind,	it	becomes	more	important	than	ever	to	
better	understand	the	fine	balance	that	exists	between	PI(3,4,5)P3	and	PI(3,4)P2	in	
normal	cells,	as	well	as	the	changes	that	occur	at	different	stages	of	tumour	progression	
and	the	role	of	PTEN	and	other	relevant	phosphatidylinositol	lipid	phosphatases	
entangled	in	class	I	PI3K‐mediated	signalling.	These	considerations	may	have	a	pivotal	
impact	on	helping	identify	new	targets	along	the	class	I	PI3K/AKT	signalling	axis,	or	
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other	yet	unidentified	pathways,	and	may	potentially	lead	to	therapy	strategies	suited	
for	cancers	of	different	cellular	origin	and	different	stages	of	advancement.		
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